Cargando…

Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial

We present the interim results of the efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac. This was a randomized, observer-blinded, non-inferiority trial (NCT04942405). Volunteers were 18–55 years old and randomized at a 1:1 ratio to receive either TURKOVAC or...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanriover, Mine Durusu, Aydin, Ozlem Altuntas, Guner, Rahmet, Yildiz, Orhan, Celik, Ilhami, Doganay, Hamdi Levent, Kose, Sukran, Akhan, Sila, Akalin, Emin Halis, Sezer, Zafer, Ozdarendeli, Aykut, Unal, Serhat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698857/
https://www.ncbi.nlm.nih.gov/pubmed/36366373
http://dx.doi.org/10.3390/vaccines10111865
_version_ 1784838924698386432
author Tanriover, Mine Durusu
Aydin, Ozlem Altuntas
Guner, Rahmet
Yildiz, Orhan
Celik, Ilhami
Doganay, Hamdi Levent
Kose, Sukran
Akhan, Sila
Akalin, Emin Halis
Sezer, Zafer
Ozdarendeli, Aykut
Unal, Serhat
author_facet Tanriover, Mine Durusu
Aydin, Ozlem Altuntas
Guner, Rahmet
Yildiz, Orhan
Celik, Ilhami
Doganay, Hamdi Levent
Kose, Sukran
Akhan, Sila
Akalin, Emin Halis
Sezer, Zafer
Ozdarendeli, Aykut
Unal, Serhat
author_sort Tanriover, Mine Durusu
collection PubMed
description We present the interim results of the efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac. This was a randomized, observer-blinded, non-inferiority trial (NCT04942405). Volunteers were 18–55 years old and randomized at a 1:1 ratio to receive either TURKOVAC or CoronaVac at Day 0 and Day 28, both of which are 3 μg/0.5 mL of inactivated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) adsorbed to aluminum hydroxide. The primary efficacy outcome was the prevention of polymerase chain reaction (PCR)-confirmed symptomatic coronavirus disease 2019 (COVID-19) at least 14 days after the second dose in the modified per-protocol (mPP) group. Safety analyses were performed in the modified intention-to-treat (mITT) group. Between 22 June 2021 and 7 January 2022, 1290 participants were randomized. The mITT group consisted of 915 participants, and the mPP group consisted of 732 participants. During a median follow-up of 90 (IQR 86–90) days, the relative risk reduction with TURKOVAC compared to CoronaVac was 41.03% (95% CI 12.95–60.06) for preventing PCR-confirmed symptomatic COVID-19. The incidences of adverse events (AEs) overall were 58.8% in TURKOVAC and 49.7% in CoronaVac arms (p = 0.006), with no fatalities or grade four AEs. TURKOVAC was non-inferior to CoronaVac in terms of efficacy and demonstrated a good safety and tolerability profile.
format Online
Article
Text
id pubmed-9698857
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96988572022-11-26 Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial Tanriover, Mine Durusu Aydin, Ozlem Altuntas Guner, Rahmet Yildiz, Orhan Celik, Ilhami Doganay, Hamdi Levent Kose, Sukran Akhan, Sila Akalin, Emin Halis Sezer, Zafer Ozdarendeli, Aykut Unal, Serhat Vaccines (Basel) Article We present the interim results of the efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac. This was a randomized, observer-blinded, non-inferiority trial (NCT04942405). Volunteers were 18–55 years old and randomized at a 1:1 ratio to receive either TURKOVAC or CoronaVac at Day 0 and Day 28, both of which are 3 μg/0.5 mL of inactivated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) adsorbed to aluminum hydroxide. The primary efficacy outcome was the prevention of polymerase chain reaction (PCR)-confirmed symptomatic coronavirus disease 2019 (COVID-19) at least 14 days after the second dose in the modified per-protocol (mPP) group. Safety analyses were performed in the modified intention-to-treat (mITT) group. Between 22 June 2021 and 7 January 2022, 1290 participants were randomized. The mITT group consisted of 915 participants, and the mPP group consisted of 732 participants. During a median follow-up of 90 (IQR 86–90) days, the relative risk reduction with TURKOVAC compared to CoronaVac was 41.03% (95% CI 12.95–60.06) for preventing PCR-confirmed symptomatic COVID-19. The incidences of adverse events (AEs) overall were 58.8% in TURKOVAC and 49.7% in CoronaVac arms (p = 0.006), with no fatalities or grade four AEs. TURKOVAC was non-inferior to CoronaVac in terms of efficacy and demonstrated a good safety and tolerability profile. MDPI 2022-11-04 /pmc/articles/PMC9698857/ /pubmed/36366373 http://dx.doi.org/10.3390/vaccines10111865 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Tanriover, Mine Durusu
Aydin, Ozlem Altuntas
Guner, Rahmet
Yildiz, Orhan
Celik, Ilhami
Doganay, Hamdi Levent
Kose, Sukran
Akhan, Sila
Akalin, Emin Halis
Sezer, Zafer
Ozdarendeli, Aykut
Unal, Serhat
Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
title Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
title_full Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
title_fullStr Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
title_full_unstemmed Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
title_short Efficacy, Immunogenicity, and Safety of the Two-Dose Schedules of TURKOVAC versus CoronaVac in Healthy Subjects: A Randomized, Observer-Blinded, Non-Inferiority Phase III Trial
title_sort efficacy, immunogenicity, and safety of the two-dose schedules of turkovac versus coronavac in healthy subjects: a randomized, observer-blinded, non-inferiority phase iii trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9698857/
https://www.ncbi.nlm.nih.gov/pubmed/36366373
http://dx.doi.org/10.3390/vaccines10111865
work_keys_str_mv AT tanrioverminedurusu efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT aydinozlemaltuntas efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT gunerrahmet efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT yildizorhan efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT celikilhami efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT doganayhamdilevent efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT kosesukran efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT akhansila efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT akalineminhalis efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT sezerzafer efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT ozdarendeliaykut efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT unalserhat efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial
AT efficacyimmunogenicityandsafetyofthetwodoseschedulesofturkovacversuscoronavacinhealthysubjectsarandomizedobserverblindednoninferiorityphaseiiitrial